UCI School of Medicine Department of Obstetrics & Gynecology



Advanced Course in Cytoreductive Surgery for Gynecologic Peritoneal Surface Malignancies:

Radical Pelvic and Upper Abdominal Procedures with Cadaver Dissection

May 29 – 31 2025

Hyatt Huntington Beach Resort 21500 E. Pacific Coast Hwy. Huntington Beach, CA

Co-Sponsored by



Course Director



Robert E. Bristow, MD, MBA Chair, Department of Obstetrics and Gynecology Edward J. Quilligan Administrative Chair UCI School of Medicine

Course Co-Directors



Dennis S. Chi, MD Memorial Sloan Kettering Cancer Center New York City, NY



William Cliby, MD Mayo Clinic Rochester, MN



Christina Fotopoulou, MD, PhD Imperial College of London Healthcare NHS Trust, Queen Charlotte's and Chelsea Hospital London, United Kingdom



Ane Gerda Zahl Eriksson, MD, PhD Norwegian Radium Hospital Oslo, Norway

UCI Faculty



Krishnansu S. Tewari, MD Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology UCI School of Medicine



Jill Tseng, MD Assistant Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology UCI School of Medicine



Michael O'Leary, MD Assistant Professor, Division of Surgical Oncology, Department of Surgery, UCI School of Medicine

Guest Faculty



Ahmed Al-Niaimi, MD Memorial Sloan Kettering Cancer Center New York City, NY



Suk-Joon Chang, MD, PhD Ajou University Hospital Suwon, South Korea



Carrie Langstraat, MD Mayo Clinic Rochester, MN



Kara Long-Roche, MD Memorial Sloan Kettering Cancer Center New York City, NY



Oliver Zivanovic, MD, PhD Heidelberg University Hospital Heidelberg, Germany



Oliver Eng, MD Associate Professor, Division of Surgical Oncology, Department of Surgery Associate Director, Peritoneal Malignancy Program, Department of Surgery UCI School of Medicine



Zeljka Jutric, MD Assistant Professor, Division of Hepatobiliary and Pancreas Surgery and Islet Cell Transplantation, Department of Surgery UCI School of Medicine

Advanced Course in Cytoreductive Surgery

Purpose of the Course

The thoroughness of cytoreductive surgery is a primary contributor to survival for patients with advanced ovarian and primary peritoneal carcinoma. This program is designed to provide information through formal lectures, panel discussions, and cadaver dissection about clinical applications of advanced cytoreductive surgery for ovarian cancer and related gynecologic peritoneal surface malignancies.

Target Audience

This activity is designed for physicians and surgeons who practice this specialty of gynecologic oncology and surgical oncology.

Learning Objectives

After completing this learning activity, the participant should be able to:

- Describe the prognostic impact of minimal residual disease achievable through advanced cytoreductive surgical procedures.
- Discuss the advantages, limitations and indications for advanced cytoreductive surgery in gynecological practice.
- Describe the critical steps in performing advanced cytoreductive surgical procedures in gynecology.

Registration

Registration for this course is available at https://my.sgo.org/s/community-event?id=a1YVs000000k9LF To ensure a spot in this course, early registration is strongly encouraged.

Course Registration Fees

Physicians and Surgeons - SGO Member \$2,000, SGO Non-Member \$2,500

Fellows and Residents - SGO Member \$1,500, SGO Non-Member \$1,875

Registration fees include both days of the conference, the evening reception, continental breakfast, lunch and CME certificate. For more information, contact Jenille Powers at japowers@hs.uci.edu

Accreditation Statement

The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The University of California, Irvine School of Medicine designates this live activity of a maximum of 19.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

It is the policy for the University of California, Irvine School of Medicine and University of California CME consortium to ensure balance, independence, objectivity and scientific rigor in all CME activities. Full disclosure or conflict and resolution will be made in writing via handout materials of syllabus.

Acknowledgment of Commercial Support

The University of California, Irvine School of Medicine thank Medtronic for their in-kind support of this educational activity.

Accommodations

Hyatt Regency Huntington Beach Resort & Spa 21500 Pacific Coast Hwy Huntington Beach, CA 92648 (714) 698-1234

Hotel Room Block:

Special discounted hotel room rates will be available for early booking as space is limited. We recommend making travel arrangements early. A room rate of \$359 a night is guaranteed for conference attendees through May 7, 2025. Contact the hotel directly for reservations at (714) 698-1234 and reference Group Code G-F118 or click <u>HERE</u>. All attendees are responsible for their own reservations. The standard hotel individual reservation cancellation policy will apply.



California Assembly Bill 1195 and 241

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, https://medschool.uci.edu/cme for AB 1195 and AB 241 resources.

ADA Statement

In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your needs. For any special requests, please contact Jenille Powers at japowers@hs.uci.edu on or before April 28, 2025.

THURSDA MAY 29

FRIDAY MAY 30

SATURDAY MAY 31

AGENDA

6:45 - 7:00am
7:00 - 7:15am
7:15 - 7:45am
7:45 - 8:30am
8:30 - 9:00am
9:00 - 9:30am
9:30 - 10:15am
10:15 - 11:15am

11:15 - 12:00pm

12:00 - 1:00pm

1:00 - 1:30pm 1:30 - 2:30pm 2:30 - 3:00pm 3:00 - 3:30pm **3:30pm 6:00pm**

6:45 - 7:00am 7:00 - 7:45am 7:45 - 8:15am 8:15 - 9:15am

9:15 - 10:00am 10:00 - 11:00am

11:00 - 11:45am

11:45 - 12:15pm 12:15 - 1:15pm 1:15 - 1:45pm 1:45 - 2:15pm 2:15 - 3:00pm 3:00pm 4:00 - 6:00pm

6:45 - 7:00am 7:15 - 8:00am 8:00 - 11:30am 11:30 - 12:15pm 12:15 - 3:45pm 4:00pm

Breakfast

Welcome and Introduction (Bristow) Cytoreductive Surgery: History & Rationale (Long-Roche) Liver, Gallbladder, Porta Hepatis (Jutric) Pre-operative Preparation & Post-operative Care (Eriksson) Surgical Armamentarium & Strategic Approach (Bristow) **Break/Small Group Discussion** Radical Oophorectomy & the Rectosigmoid Colectomy (Bristow/Fotopoulou) Triage Primary Surgery vs NACT and Anastomotic Leak Prevention (Cliby/Langstraat) Lunch Morison's Pouch, Lesser Sac & Lesser Omentum (Al-Niami) Diaphragm & Thoracic Surgery (Chang/Chi) HIPEC/HITEC (O'Leary) Ovarian Cancer State of the Science Therapeutics (Tewari) Adjourn **Group Dinner**

Breakfast

Enhanced Recovery After Surgery & "Red Rules" (Long-Roche) Celiac Axis, Nephrectomy, Adrenalectomy (Al-Niami) Spenectomy, Distal Pancreatectomy & Multivisceral Resection (Bristow/Cliby) **Break/Small Group Discussion** Pelvic & Para-aortic Lymphadenectomy & Debulking (Fotopoulou/Langstraat) Extrapelvic Bowel Surgery & Management of Obstruction (Fotopoulou) Control of Hemorrhage & Surgical Adjuvants (Tseng) Lunch Management of Colorectal Cancer Peritoneal Metastasis (Eng) Bowel Surgery Complications (Zivanovic) Secondary Cytoreductive Surgery (Chang) Adjourn **Cocktail Reception**

Breakfast

Transit to UC Irvine Medical Center Lab Session 1: Right & Left Upper Abdomen Lunch Session 2: Abdominal Retroperitoneum, Bowel Surgery, Pelvis Adjourn

Mitigation of Relevant Financial Relationships

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information	Role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Robert Bristow, MD, MBA Chair and Professor UC Irvine	Course Director, Faculty	Nothing to disclose
Ahmed Al-Niaimi, MD, Professor of Gynecologic Oncology Professor of Gynecologic Oncology Memorial sloan kettering Cancer Center	Faculty	Nothing to disclose
Suk-Joon Chang, MD, PhD Professor Ajou University School of Medicine Korea, Republic Of	Faculty	Nothing to disclose
Oliver Eng, MD Associate Professor UC Irvine	Faculty	Speakers Bureau-Tempus Labs, Inc.
Ane Gerda Z Eriksson, MD, PhD Dr. The Norwegian Radiumhospital, Oslo University Hospital Norway	Faculty	Nothing to disclose
Christina Fotopoulou, MD, PhD Imperial COllege London United Kingdom	Faculty	Advisor-Roche (Any division) Advisor-Oncoinvent, GSK Advisor-AstraZeneca (Any division)
Zeljka Jutric, MD UCI	Faculty	Nothing to disclose
Carrie Langstraat, MD Mayo Clinic	Faculty	Nothing to disclose
Kara Long, MD Associate Attending Memorial Sloan Kettering Cancer Center	Faculty	Nothing to disclose
Michael P O'Leary, MD UCI School of Medicine	Faculty	Nothing to disclose
Krishnansu S Tewari, MD UC Irvine Health	Faculty	Consulting Fee-Merck (Any division) Consulting Fee-AstraZeneca (Any division) Consulting Fee-Eisai, Inc. Consulting Fee-Seagen Consulting Fee-GSK Speakers Bureau-Eisai, Inc. Speakers Bureau-Merck (Any division) Speakers Bureau-GSK Speakers Bureau-Seagen
Jill Tseng, MD Dr UC Irvine Health	Faculty	Nothing to disclose
Oliver Zivanovic, MD, PhD	Faculty	Nothing to disclose
Dennis S Chi, MD MD MSKCC	Faculty, Other Planning Committee Member	Honoraria-AstraZeneca (Any division) Stocks or stock options, excluding diversified mutual funds- Doximity (Relationship has ended) Stocks or stock options, excluding diversified mutual funds- BioNTech (Relationship has ended)
William Cliby, MD Mayo Clinic	Faculty, Other Planning Committee Member	Nothing to disclose